PLx Pharma Present at the Sidoti & Company Fall 2017 Conference
September 18 2017 - 3:30PM
PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a
late-stage specialty pharmaceutical company focused on
commercializing two patent-protected products, Aspertec™ 325 mg and
Aspertec™ 81 mg (referred to together as “Aspertec”™), today
announced that Natasha Giordano, President and Chief Executive
Officer, and Rita O’Connor, Chief Financial Officer, will present
at the Sidoti & Company Fall 2017 Conference as follows:
Date: Thursday, September 28,
2017Time: 9:40am Eastern Daylight Time
Location: New York Marriott Marquis, New York
CityWebcast:
http://www.investorcalendar.com/event/20263
The presentation will be webcast live at the aforementioned
time, and archived for 30 days thereafter, via the Company’s
website at www.plxpharma.com, under the Investors Section.
About AspertecAspertec 325 mg is
an FDA-approved aspirin product being developed to provide
high-risk cardiovascular and stroke patients with more reliable and
predictable antiplatelet efficacy as compared to enteric-coated
aspirin, while also reducing the adverse gastric events common in
an acute setting. PLx is focused on completing manufacturing
scale-up and label finalization for Aspertec 325 mg aspirin dosage
form and preparing an sNDA for Aspertec 81 mg maintenance dose
form.
About PLx Pharma Inc.PLx Pharma
Inc. is a late-stage specialty pharmaceutical company focused
on developing its clinically validated and patent-protected
PLxGuard™ delivery system to provide safe and effective aspirin
products. The PLxGuard delivery system works by targeting delivery
of active pharmaceutical ingredients (API) to various portions of
the gastrointestinal (GI) tract. PLx believes this has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce acute GI side
effects—including erosions, ulcers and bleeding—associated with
aspirin and ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
About Sidoti & Company
Sidoti & Company, LLC is Wall Street’s
preeminent provider of equity research generally focused on
companies with market capitalizations of under $3 billion. We cover
over 250 companies across a range of industries. The companies
covered by our traditional research typically have a history of
profitability, maintain strong balance sheets, and tend to have
limited, if any, coverage by other Wall Street firms.
Our approach affords institutional investor
clients a combination of high-quality research, a small- and
micro-cap company focused nationwide sales effort, broad access to
corporate management teams, and extensive trading support. We serve
nearly 500 institutional clients in the U.S., Canada and the U.K.,
including many leading managers of portfolios with $200 million to
$2 billion of assets. We believe that these asset managers are
generally underserved by other larger brokerage firms that
typically target larger managers.
Sidoti also hosts a fee-based biannual
conference in New York, and is a provider of company sponsored
research.
We are a broker-dealer registered with the SEC
and a FINRA member firm. We provide a broad range of
securities-related services. In addition to our high-quality
research, our sales and trading services are distinguished by
prompt execution, a competitive commission structure and access to
smart order routing that utilizes all available sources of
liquidity. From time to time, we are invited to participate as an
underwriter, dealer, placement agent or initial purchaser in
securities offerings for issuers for which we provide research
coverage. Given our knowledge of the companies we cover, we believe
that we are able to contribute to these capital-raising
transactions. We also assist our issuers with stock repurchase
programs, block trades and organized (Rule 10b5-1) trading
plans.
Contact Investor Relations:Lisa M. Wilson,
In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Source: PLx Pharma Inc.
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Apr 2024 to May 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From May 2023 to May 2024